Cheshire
Senior Member (Voting Rights)
Some interresting considerations about trials methodology (CoI, selectivity in publishing trials with positive results, gap between patients selected and real life patients, scales, what is used as a placebo...)
https://aeon.co/essays/the-evidence...G0isq49Qtq5PIFtBnRSR-xeJJSIwggXT7VuswjGUZgBqY
Rings a bell?The problem with this scale is that large changes in a subject’s score can occur as a result of trivial changes in a subject’s real depression. For example, there are three questions about the quality of a subject’s sleep, with a total of six possible points, and there is a question about how much a subject is fidgeting, with up to four points. So a drug that simply made people sleep better and fidget less could lower one’s depression score by 10 points. To put this in context, recent clinical guidelines in the UK have required drugs to lower depression scores on this scale by an average of only three points. When a measurement scale measures what we want it to measure, we say the scale has ‘construct validity’. The general problem with depression-severity scales is that they lack construct validity, and this contributes to overestimating the effectiveness of antidepressants.
https://aeon.co/essays/the-evidence...G0isq49Qtq5PIFtBnRSR-xeJJSIwggXT7VuswjGUZgBqY